Spero Therapeutics, Inc. (SPRO) Financial Analysis & Valuation | Quarter Chart
Spero Therapeutics, Inc. (SPRO)
SPROPrice: $2.41
Fair Value: 🔒
🔒score
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobr... more
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, develo... more
Description
Shares
| Market Cap | $135.62M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Esther P. Rajavelu |
| IPO Date | 2017-11-02 | CAGR | — |
| Employees | 32 | Website | sperotherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SPRO chart loading...
Fundamentals
Technicals
| Enterprise Value | $60.54M | P/E Ratio | -2.51 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 4.18 | P/B Ratio | 5.12 |
| P/CF Ratio | -4.9 | P/FCF Ratio | -4.9 |
| EPS | $-0.98 | EPS Growth 1Y | -1243.29% |
| EPS Growth 3Y | -74.99% | EPS Growth 5Y | -81.04% |
| Revenue Growth 1Y | -62.36% | Gross Margin | 0.83% |
| Operating Margin | -1.44% | Profit Margin | -1.38% |
| ROE | -1.28% | ROA | -0.83% |
| ROCE | -1.16% | Current Ratio | 3.83 |
| Quick Ratio | 3.83 | Cash Ratio | 3.56 |
| Debt/Equity | 0.13 | Interest Coverage | — |
| Altman Z Score | -10.91 | Piotroski Score | 2 |